← Upcoming Courses
The Cardio-Renal Metabolic (CRM) Regional Webinar is a CPD training designed to strengthen clinical decision-making at the intersection of cardiology, nephrology, and metabolic care. Participants will review the interdependence of the heart, kidneys, and metabolic health and their implications for patients with cardiorenal-metabolic (CRM) conditions.
The programme combines concise talks, case-based application, a high-level panel discussion, and extended Q&A. Sessions will emphasize timely therapy selection, risk stratification, and integrated follow-up.
TOPICS TO BE PRESENTED
- Beyond Silos: Understanding the Heart-Kidney-Metabolic interconnectivities for CRM patient.
- Protecting Kidneys Early in CRM Patients with Empagliflozin - What Does the Evidence Tell Us?
WHY YOU SHOULD ATTEND
- Understand Cardiorenal-Metabolic Interconnections.
- Gain insights into the relationship between cardiovascular, kidney and metabolic health and their impact on patient outcomes.
- Learn why early identification and intervention are essential for protecting kidney function in patients with CRM conditions.
- Explore evidence on Empagliflozin.
- Earn accredited CPD points with practical take-aways you can apply on the next clinic day.
- Engage directly with expert faculty during an extended Q&A and panel discussion.
PROUDLY SPONSORED BY
This is a virtual event scheduled for Friday the 20th of November, 2026 at 15:30 GMT.
Target Audience: Family Medicine Physicians; Internists; Endocrinologists/Diabetologists; Nephrologists; General Practitioners.
Date: Friday, 20th November, 2026
Time: 15:30 GMT (3:30 PM Local Time)
The sessions and Q&A will be moderated by DR. UNNIKRISHNAN A G. - Consultant Endocrinologist
Don’t miss out on this exciting opportunity to elevate your skills and make a lasting impact in CRM!
PARTICIPANT CONSENT AND DATA PRIVACY NOTICE
By registering for the “Cardio-Renal Metabolic (CRM) Webinar 4”, you consent to participate in this training hosted by Continuous Education Services (CES) on behalf of Boehringer Ingelheim (BI) and DP World. Your registration will provide us with the necessary information to facilitate the event and issue CPD accreditation through the Medical and Dental Council (MDC). CES is committed to safeguarding your personal information and will not share any personal data with BI or DP World. Your data will only be shared with the relevant regulatory bodies, such as MDC, solely for accrediting CPD points earned through this training. Participants are free to opt out of the meeting at any time; no further action is required on your part. Your privacy is respected, and your participation will be treated with the highest level of confidentiality.
Overview
Course Description
This webinar will explore the interconnections between cardiovascular, kidney, and metabolic health in patients with cardiorenal-metabolic (CRM) conditions, highlighting how these systems influence disease progression and patient outcomes. The session will examine the clinical significance of understanding heart-kidney-metabolic interconnectivity and its implications for comprehensive patient management. Participants will also explore the importance of early kidney protection in CRM patients, focusing on the evidence supporting empagliflozin and its role in preserving kidney function and improving clinical outcomes. Expert presentations will discuss current clinical evidence, therapeutic considerations, and the value of timely intervention in reducing the risk of kidney complications. Designed for family physicians, internists, endocrinologists, nephrologists, and GPs, the programme prioritizes immediately actionable skills and accredited learning.
What you will learn
By the end of the webinar, participants should be able to:
1. Explain the interconnections between cardiovascular, kidney, and metabolic health and their implications for patients with cardiorenal-metabolic (CRM) conditions.
2. Describe the impact of heart-kidney-metabolic interactions on disease progression and clinical outcomes in CRM patients.
3. Discuss the importance of early kidney protection in CRM patients and the benefits of timely therapeutic intervention.
4. Evaluate the clinical evidence supporting the use of empagliflozin for kidney protection in patients with CRM conditions.
5. Apply evidence-based strategies to support integrated, patient-centered management of CRM patients and improve clinical outcomes.
Course Content
Lecture Sessions
- LIVE EVENT: Friday 20th November, 2026 @ 15:30 GMT (3:30 pm) 2 hours
Downloadables
No downloadable content added to this course yet.
About Facilitators
- 1 Course on CES
Professor Per-Henrik Groop
MD, DMSc, FRCPE
Chief Physician,
Department of Nephrology — Helsinki University Hospital, Finland.
Professor Per-Henrik Groop, MD, DMSc, FRCPE, is an Emeritus Professor of Internal Medicine at the University of Helsinki, Finland, and Emeritus Chief Physician at the Department of Nephrology, Helsinki University Hospital.
View full profile / courses
- 1 Course on CES
Dr Lyndon Marc Evans
MB BCh, MD, FRCP (UK)
Medical Researcher | Editor-in-Chief of Diabetes Therapy
Dr Lyndon Marc Evans, MB BCh, MD, FRCP (UK), is a medical professional and researcher with expertise in diabetes, cardiovascular disease, lipid metabolism, and the clinical and economic evaluation of treatments.
View full profile / courses
